Accelerating access to revolutionary cell and gene therapies with next generation tools and technology platforms

 
A_Banner.jpg
 
 

About Us

Anjarium Biosciences AG is a cell and gene therapy tools and technology company based in Switzerland and the U.S.  Anjarium is capable of designing, manufacturing and supplying synthetic DNA as well as targeted non-viral vectors for the delivery of a diverse set of payloads. 

We are advancing two novel technology platforms both of which are poised to disrupt current best-in-class technologies enabling improved access to genetic medicines:

  • pxDNA is our cell-free platform for manufacturing synthetic linear DNA.  Our scalable process stands ready to replace plasmid DNA as an alternative enabling transformative biotechnology solutions for genetic medicines.

  • Our innovative resin technology has demonstrated significantly better recovery of enveloped viruses and exosomes compared to industry leading technologies. 

 
 

Our Approach

pxDNA is our cell-free platform for manufacturing synthetic linear DNA.  Our patented technology offers faster turnaround time, less impurities, higher copy number and minimal footprint requirements compared to plasmid DNA. pxDNA is well positioned to replace plasmid DNA as a key starting material for AAV, mRNA, Lentivirus and other cell and gene therapy modalities.

Our resin technology has demonstrated significantly better enveloped virus recovery compared to industry leading technologies and is poised to meaningfully reduce COGS and improve patient access to novel therapies. 

 

Investors

Investors in Anjarium include Abingworth, Gimv, Omega Funds, Surveyor Capital (a Citadel company) and Pfizer Ventures.

abingworth.jpg
gimv.jpg
omega.jpg
surveyor.jpg
pfizer.png
News-bg.jpg


Careers

Join us in transforming how life-changing genetic medicines are created

Anjarium is assembling a world-class global team to accelerate access to revolutionary cell and gene therapies with next generation tools and technology platforms.